Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.
Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.
Depends on raising capital and licensing deals to fund trials. Oncolytic viruses are viruses engineered to infect and destroy cancer cells while sparing healthy tissue; Telomelysin uses a viral control element that switches on only in cells with an active telomerase, an enzyme most cancers use.
In one line: A small-cap Japanese oncolytic-virus biotech, akin to early Replimune.
Moat: narrow (IP / patents). Proprietary oncolytic-virus technology platform, though still largely pre-commercial.
Headquarters: Tokyo, Japan · Founded: 2004 · Employees: 38
Size Oncolys BioPharma (4588.T) is a Japan Health Care company (Biotechnology) with a market value of $1.37B, the 606th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥7,540 on 18 Nov 2026.
Performance Over six months the shares gained 181.3%, against -18.9% for the median peer and -1.4% for the Japan market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 1,749.0% over the last twelve months (peer median +24.8%); the operating margin is -295.1% (peer median -179.2%).
Valuation It trades at 408.9× enterprise value to sales against a peer median of 21.3× (2nd most expensive of 18).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥528M | ¥28.5M | ¥31.4M | ¥63.0M | ¥976M |
| Revenue growth | — | -9% | -50% | -94% | — |
| Gross profit | ¥527M | ¥28.3M | ¥30.6M | ¥30.6M | ¥338M |
| EBITDA | -¥1.56B | -¥2.02B | -¥1.68B | -¥1.93B | -¥1.20B |
| Net income | -¥1.56B | -¥2.06B | -¥1.68B | -¥1.94B | -¥1.15B |
| Free cash flow | n/a | -¥1.94B | -¥2.02B | -¥1.34B | -¥1.72B |
| Capital expenditure | n/a | ¥3.01M | ¥3.52M | ¥5.69M | ¥1.36M |
| Total debt | ¥232M | ¥320M | ¥325M | ¥315M | ¥394M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oncolys BioPharma 4588.T | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a |
| Replimune REPL | $1.88B | +321% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 2.2× | -9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4588.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +46.1% | -15.3% | highest of 21 |
| 6-month return | +181.3% | -18.9% | highest of 19 |
| Distance from 52-week high | -12.3% | -47.0% | highest of 21 |
| Revenue growth (TTM) | +1,749.0% | +24.8% | highest of 18 |
| Operating margin | -295.1% | -179.2% | 10th highest of 19 |
| EV / Sales | 408.9× | 21.3× | 2nd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |